Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Search
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com
Lung Cancer
Find out more about lung cancer, the second most common cancer worldwide, that claims more lives each year than any other type.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Supporting local communities by offsetting carbon emissions
Boehringer Ingelheim partially offsets its carbon emissions by partnering with ClimateSeed
George Okafo
My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Veronika Kohlbrenner
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Supporting grooms in equestrian sports
Find out how one organization can change the lives of those who dedicate their careers to horse care.
Boehringer Ingelheim Advances Oncology Research
Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Catherine Alonzo
Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
Veterinarians go beyond: animal care and veterinary medicine
We surveyed over 1000 veterinarians from six countries. Did you know that only 49% of respondents think that the veterinary profession is appreciated?
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Stroke Risk Factors Symptoms
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results